578. Identification of BCG Osteitis in Paraffin-blocked Pathologic Specimens in the Repulic of Korea
Session: Poster Abstract Session: Non-Tuberculosis Mycobacterial
Thursday, October 27, 2016
Room: Poster Hall
  • 2016 배길성 IDWeek BCG osteitis.pdf (385.0 kB)
  • Background:BCG osteitis is a rare systemic adverse reaction following BCG vaccination. Diagnosis of BCG osteitis has been challenging, because of the difficulty in the distinction from the osteitis caused by Mycobacterium tuberculosis. With several cases of BCG osteitis that were confirmed by the molecular methods, this study aimed to identify the proportion of BCG osteitis among the specimens which had been diagnosed as Mycobacterium tuberculosis osteitis.

    Methods:Paraffin-blocked specimens were collected which had been diagnosed as Mycobacterium tuberculosis osteitis at five hospitals. Tests for molecular differentiation were done twice for every specimen. Real-time PCR of the IS6110 gene and SenX3-RegX3 gene was conducted in order to distinguish Mycobacterium bovis BCG from non-BCG Mycobacterium tuberculosis Complex. Real-time PCR of the 16S rRNA gene, hsp65 gene, 16S rRNA hypervariable sequence was conducted in order to distinguish MTBC from non-tuberculosis Myobacteria. Multiplex real-time PCR of the region of difference 1, 8, 14 was used for the differentiation of the Mycobacterium bovis BCG strain. Base sequencing of the Exact Tandem Repeat D between SenX3 and RegX3 was used for the identification of MTBC including the Mycobacterium bovisBCG strain. In addition, medical records of the confirmed BCG osteitis from participating hospitals were reviewed.

    Results:A total of 104 specimens were collected from 49 patients. Of the 49 patients, 15 patients (30.6%) showed positive gene amplification for mycobacteria: confirmed Mycobacterium tuberculosis infection in 6 patients; probable Mycobacterium tuberculosis infection in 3 patients; probable Mycobacterium bovisBCG infection in 6 patients. Mean age at the diagnosis of the 12 patients was 20.25 months. Ten out of 12 cases received Tokyo strain BCG percutaneously. Most commonly affected site was knee joint in 6 (50.0%) of 12 patients.

    Conclusion:Molecular tests that can distinguish Mycobacterium bovis BCG from Mycobacterium tuberculosis demonstrated that 40% (6/15) of the formerly diagnosed Mycobacterium tuberculosis osteitis might be BCG osteitis. The present findings suggest that BCG osteitis may be underrecognized in the countries where BCG is routinely vaccinated and molecular distinction is warranted for the cases when mycobacterial infection is suggested.

    Kil Seong Bae, MD1, Joon Kee Lee, MD2, Jae Hong Choi, MD3, Eun Hwa Choi, MD, PhD2, Hoan Jong Lee, MD, PhD2 and Jong-Hyun Kim, MD, PhD4, (1)St. Vincent's Hospital, College of Medicine, Suwon, Korea, The Republic of, (2)Department of Pediatrics, Seoul National University Hospital, Seoul, Korea, The Republic of, (3)Pediatrics, Seoul National University Bundang Hospital, Seongnam, South Korea, (4)Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of


    K. S. Bae, None

    J. K. Lee, None

    J. H. Choi, None

    E. H. Choi, None

    H. J. Lee, None

    J. H. Kim, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.